Bailing Xu

1.1k total citations
53 papers, 907 citations indexed

About

Bailing Xu is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Bailing Xu has authored 53 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 20 papers in Oncology and 14 papers in Organic Chemistry. Recurrent topics in Bailing Xu's work include Signaling Pathways in Disease (13 papers), PARP inhibition in cancer therapy (11 papers) and Toxin Mechanisms and Immunotoxins (11 papers). Bailing Xu is often cited by papers focused on Signaling Pathways in Disease (13 papers), PARP inhibition in cancer therapy (11 papers) and Toxin Mechanisms and Immunotoxins (11 papers). Bailing Xu collaborates with scholars based in China, United States and India. Bailing Xu's co-authors include Xiaoguang Chen, Jie Zhou, Xiaodong J. Wang, Felicia A. Etzkorn, Jing Jin, Ming Ji, Ran Cao, Hailong Zhao, Jeffrey W. Peng and Andrew T. Namanja and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Brain Research.

In The Last Decade

Bailing Xu

49 papers receiving 891 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bailing Xu China 19 567 303 298 168 68 53 907
Benjamin P. Fauber United States 16 637 1.1× 280 0.9× 384 1.3× 257 1.5× 23 0.3× 24 1.3k
G.M. Robertson United Kingdom 13 393 0.7× 328 1.1× 306 1.0× 98 0.6× 83 1.2× 27 874
Aude Echalier United Kingdom 21 729 1.3× 377 1.2× 245 0.8× 42 0.3× 53 0.8× 29 1.3k
Paul Bauer Sweden 21 981 1.7× 189 0.6× 104 0.3× 62 0.4× 40 0.6× 48 1.3k
Kuiying Xu United States 19 615 1.1× 310 1.0× 137 0.5× 39 0.2× 73 1.1× 47 1.2k
Masaichi Warizaya Japan 13 339 0.6× 198 0.7× 101 0.3× 63 0.4× 76 1.1× 22 592
Giovanna Zinzalla United Kingdom 18 640 1.1× 229 0.8× 339 1.1× 77 0.5× 18 0.3× 31 997
Keizo Koya United States 19 627 1.1× 205 0.7× 406 1.4× 105 0.6× 11 0.2× 31 1.2k
Samit K. Bhattacharya United States 17 269 0.5× 153 0.5× 353 1.2× 43 0.3× 32 0.5× 29 803
Vered Klinghofer United States 21 580 1.0× 338 1.1× 372 1.2× 99 0.6× 61 0.9× 27 1.3k

Countries citing papers authored by Bailing Xu

Since Specialization
Citations

This map shows the geographic impact of Bailing Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bailing Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bailing Xu more than expected).

Fields of papers citing papers by Bailing Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bailing Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bailing Xu. The network helps show where Bailing Xu may publish in the future.

Co-authorship network of co-authors of Bailing Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Bailing Xu. A scholar is included among the top collaborators of Bailing Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bailing Xu. Bailing Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xiaoyu, Jie Zhou, & Bailing Xu. (2025). Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses. Bioorganic Chemistry. 160. 108471–108471.
2.
Zhou, Jie, et al.. (2025). Discovery of Isobenzofuran-1(3H)-one Derivatives as Selective TREK-1 Inhibitors with In Vitro and In Vivo Neuroprotective Effects. Journal of Medicinal Chemistry. 68(5). 5804–5823. 1 indexed citations
3.
Wu, Jun, Jie Zhou, Xiaoyu Wang, et al.. (2025). Discovery of Novel Isoindolin-1-one Derivatives as GABAA Receptors Positive Allosteric Modulators with Antiepileptic Efficacy. Journal of Medicinal Chemistry. 68(16). 17538–17564.
4.
Wang, Xiaoyu, Xinyuan Zhang, Jie Zhou, et al.. (2023). An in silico investigation of Kv2.1 potassium channel: Model building and inhibitors binding sites analysis**. Molecular Informatics. 42(12). e202300072–e202300072. 3 indexed citations
5.
Du, Tingting, Zhihui Zhang, Jie Zhou, et al.. (2022). A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. Frontiers in Pharmacology. 13. 865085–865085. 2 indexed citations
6.
7.
Xu, Bailing, et al.. (2020). Design, synthesis and biological evaluation of novel thiazole-based derivatives as human Pin1 inhibitors. Bioorganic & Medicinal Chemistry. 29. 115878–115878. 12 indexed citations
8.
Lai, Fangfang, et al.. (2019). Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors. European Journal of Medicinal Chemistry. 188. 111985–111985. 35 indexed citations
9.
Jin, Jing, et al.. (2018). Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors. Bioorganic & Medicinal Chemistry. 26(8). 2186–2197. 25 indexed citations
10.
Zhou, Jie, Ming Ji, Zhixiang Zhu, et al.. (2017). Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. European Journal of Medicinal Chemistry. 132. 26–41. 35 indexed citations
11.
Zhao, Hailong, Ming Ji, Jie Zhou, et al.. (2017). Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors. Bioorganic & Medicinal Chemistry. 25(15). 4045–4054. 17 indexed citations
12.
Zhao, Hailong, et al.. (2016). Synthesis and Pin1 inhibitory activity of thiazole derivatives. Bioorganic & Medicinal Chemistry. 24(22). 5911–5920. 32 indexed citations
13.
Zhou, Qin, Ming Ji, Jie Zhou, et al.. (2016). Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Biochemical Pharmacology. 107. 29–40. 15 indexed citations
14.
Ji, Ming, Zhixiang Zhu, Jie Zhou, et al.. (2015). Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry. 23(4). 681–693. 38 indexed citations
15.
Liu, Shuainan, et al.. (2014). Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase. European Journal of Medicinal Chemistry. 90. 394–405. 27 indexed citations
16.
Liu, Chang, Jing Jin, Chen Liang, et al.. (2012). Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton. Bioorganic & Medicinal Chemistry. 20(9). 2992–2999. 21 indexed citations
17.
Zhou, Jie, Yi Zhang, Yiwen Cui, et al.. (2011). Synthesis and cytotoxic evaluation ofN-(4-methoxy-1H-benzo[d]imidazol-7-yl)-arylsulfonamide andN-aryl-(4-methoxy-1H-benzo[d]imidazol)-7-sulfonamide analogs of combretastatin A-4. Journal of Asian Natural Products Research. 13(4). 330–340. 2 indexed citations
18.
Xu, Bailing, Yan Sun, Ying Guo, Yingli Cao, & Tao Yu. (2009). Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry. 17(7). 2767–2774. 28 indexed citations
19.
Xu, Bailing. (2008). Synthesis of cis- and trans-3-(3,4-dihydroxybenzyl)-hexahydropyrrolo[1,2-a]piperazine-1,4-dione under Microwave Irradiation by Solid-phase. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benjamin P. Fauber Breakdown of academic impact, for papers by G.M. Robertson Breakdown of academic impact, for papers by Aude Echalier Breakdown of academic impact, for papers by Paul Bauer Breakdown of academic impact, for papers by Kuiying Xu Breakdown of academic impact, for papers by Masaichi Warizaya Breakdown of academic impact, for papers by Giovanna Zinzalla Breakdown of academic impact, for papers by Keizo Koya Breakdown of academic impact, for papers by Samit K. Bhattacharya Breakdown of academic impact, for papers by Vered Klinghofer
Rankless by CCL
2026